Huichuan G. Sun

No. 180 Fenglin Road
Xuhui, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 91 publications

Measurement of the Λ electric dipole moment with an entangled baryon-antibaryon system.

Measurement of the Λ electric dipole moment with an entangled baryon-antibaryon system.

Journal: Science (New York, N.Y.)

Published: September 03, 2026

Spatiotemporal multiomics uncover tumor ecosystem dynamics during metastatic colonization.

Spatiotemporal multiomics uncover tumor ecosystem dynamics during metastatic colonization.

Journal: Science (New York, N.Y.)

Published: July 30, 2026

Association Between Preoperative Albumin Supplementation and Postoperative Outcomes in Hypoalbuminemia Patients After Hepatocellular Carcinoma Hepatectomy: REAL Study.

Association Between Preoperative Albumin Supplementation and Postoperative Outcomes in Hypoalbuminemia Patients After Hepatocellular Carcinoma Hepatectomy: REAL Study.

Journal: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

Published: February 23, 2026

Correction: YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.

Correction: YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.

Journal: Molecular cancer

Published: January 12, 2026

Age-Adjusted Charlson Comorbidity Index Guides Risk Stratification for Hepatocellular Carcinoma Patients Treated with TACE Combined with Immune Checkpoint Inhibitors and Targeted Therapy: A Multicenter Retrospective Cohort Study.

Age-Adjusted Charlson Comorbidity Index Guides Risk Stratification for Hepatocellular Carcinoma Patients Treated with TACE Combined with Immune Checkpoint Inhibitors and Targeted Therapy: A Multicenter Retrospective Cohort Study.

Journal: Liver cancer

Published: September 10, 2025

Integrated Multi-Omics Profiling Identifies an Immunotherapy Vulnerable and Prognostic Associated Subtype in Cholangiocarcinoma.

Integrated Multi-Omics Profiling Identifies an Immunotherapy Vulnerable and Prognostic Associated Subtype in Cholangiocarcinoma.

Journal: Liver cancer

Published: August 26, 2025

Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma.

Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma.

Journal: Gut

Published: July 09, 2025

Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial.

Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: May 19, 2025

Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study.

Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study.

Journal: The Lancet. Oncology

Published: April 29, 2025

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Journal: Hepatobiliary surgery and nutrition

Published: February 28, 2025

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study.

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study.

Journal: Signal transduction and targeted therapy

Published: February 10, 2025

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Journal: Bioscience trends

Published: December 25, 2024

Showing 1-12 of 91

Last Updated: 09/26/2026